David Hall

Dr. David Hall

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2000 in Molecular Pharmacology
Verified
Journal Article
Closed access
DHDavid Hall
David Hall
Allosteric modulation is a mechanism for modifying pharmacological receptor activity that has largely been ignored in terms of therapeutic drug design, although benzodiazepine receptor ligands are an example of the serendipitous discovery of this class of compound. The current mathematical models of allosteric interactions at (particularly G-protein-coupled) receptors concentrate on the effects of the allosteric ligand on orthosteric ligand binding and ignore potential effects of these compounds on the ability of orthosteric ligands to cause receptor activation. In this report a mathematical model of allosteric interactions at pharmacological receptors has been investigated that explicitly includes effects of the allosteric ligand on receptor activation. This model uses the two-state model of receptor activation as its basis and is qualitatively consistent with currently reported behavior of allosteric modulators. The predictions of this model suggest a series of criteria that should be tested before the effects of an allosteric modulator can be quantified in a nonsystem-dependent manner. It has also been used to provide a potential mechanistic explanation for the functional effects of the A1 adenosine receptor allosteric enhancer PD 81,723 and a recently reported allosteric modulator of type 1 metabotropic glutamate receptors.

1 June 1997 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
DHDavid Hall
David Hall
PSPhilip G. Strange
Philip G. Strange

1 April 1994 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
SHSusanna M.O. Hourani
Susanna M.O. Hourani
DHDavid Hall
David Hall

15 April 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PVPandurangan Vijayanand
Pandurangan Vijayanand
KDKesta Durkin
Kesta Durkin
GHGuido Hartmann
Guido Hartmann
JMJaymin Morjaria
Jaymin Morjaria
GSGregory Seumois
Gregory Seumois
RDRatko Djukanović
Ratko Djukanović
T lymphocytes of the Th2 type are central orchestrators of airway inflammation in asthma. The mechanisms that regulate their accumulation in the asthmatic airways remains poorly understood. We tested the hypothesis that CCR4, preferentially expressed on T lymphocytes of the Th2 type, plays a critical role in this process. We enumerated by flow cytometry the CCR4-expressing T cells from blood, induced sputum, and biopsy samples of patients with asthma and control subjects. We showed a positive correlation between the numbers of peripheral blood CCR4+ T cells and asthma severity, provided evidence of preferential accumulation of CCR4+ T cells in asthmatic airways, and demonstrated that CCR4+ but not CCR4− cells from patients with asthma produce Th2 cytokines. Explanted airway mucosal biopsy specimens, acquired by bronchoscopy from subjects with asthma, were challenged with allergen and the explant supernatants assayed for T cell chemotactic activity. Allergen-induced ex vivo production of the CCR4 ligand, CCL17 was raised in explants from patients with asthma when compared with healthy controls. Using chemotaxis assays, we showed that the T cell chemotactic activity generated by bronchial explants can be blocked with a selective CCR4 antagonist or by depleting CCR4+ cells from responder cells. These results provide evidence that CCR4 might play a role in allergen-driven Th2 cell accumulation in asthmatic airways. Targeting this chemokine receptor in patients with asthma might reduce Th2 cell-driven airway inflammation; therefore, CCR4 antagonists could be an effective new therapy for asthma. This study also provides wider proof of concept for using tissue explants to study immunomodulatory drugs for asthma.

28 November 2013 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
HNH. Neighbour
H. Neighbour
LBL.‐P. Boulet
L.‐P. Boulet
CLC. Lemiere
C. Lemiere
RSR. Sehmi
R. Sehmi
RLR. Leigh
R. Leigh
PNP. Nair
P. Nair

1 May 1998 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
GWGavin Welsh
Gavin Welsh
DHDavid Hall
David Hall
AWAndrew Warnes
Andrew Warnes
PSPhilip G. Strange
Philip G. Strange
CPChristopher Proud
Christopher Proud
The ability of human and rat D2(short) and D2(long) dopamine receptors to activate microtubule‐associated protein (MAP) kinase (Erk1/2) and p70 S6 kinase has been investigated in recombinant cells expressing these receptors. In cells expressing the D2(short) receptor, dopamine activated both enzymes in a transient manner but with very different time courses, with activation of Erk being much quicker. Activation of both enzymes by dopamine was dose‐dependent and could be prevented by a range of selective dopamine antagonists. Excellent correlations were observed between the potencies of the antagonists for blocking enzyme activation and their affinities for the D2 dopamine receptor. Activation of Erk and of p70 S6 kinase via the D2 dopamine receptors was prevented by pretreatment of the cells with pertussis toxin, indicating the involvement of G proteins of the Gi or Go family. Inhibitors of phosphatidylinositol 3‐kinase (PI 3‐kinase) were found to block substantially, but not completely, activation of p70 S6 kinase by dopamine, suggesting the involvement of PI 3‐kinase‐dependent and ‐independent signalling pathways in its control by dopamine. p70 S6 kinase activation was completely blocked by rapamycin. In the case of Erk, activation was partially blocked by wortmannin or LY294002, indicating a possible link with PI 3‐kinase.